Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/2b randomized placebo-controlled adjunctive MK-1942 in mild to moderate Alzheimer's disease dementia
jRCT2031220532Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-1942 in Alzheimer's disease (AD) (3 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in ADAS-Cog11 score at Week 12, Adverse events (AEs) and 1 more. Started Jan 2023; status: completed.
02
Drugs
MK-1942
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220532.